Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

Area of Science:

• Cancer biology
• Molecular oncology
• Drug resistance mechanisms

Background:

• Histone deacetylase inhibitors (HDIs) like SAHA are a novel class of anticancer agents.
• SAHA is approved for cutaneous T cell lymphoma (CTCL) but shows limited efficacy in solid tumors.
• Understanding SAHA resistance mechanisms is crucial for improving cancer therapy.

Purpose of the Study:

• To investigate the role of oncogenic K-ras in SAHA resistance.
• To identify molecular mediators linking K-ras activation to SAHA resistance.
• To explore combination strategies involving K-ras inhibition and SAHA.

Main Methods:

• Analysis of HDAC6 and c-myc expression in K-ras-mutated cells and patient samples.
• Assessment of SAHA efficacy in K-ras-transformed cells and K-ras-mutant lung cancer cells.
• Investigation of the signaling pathways involved in K-ras-mediated resistance.
• Evaluation of K-ras inhibitors in combination with SAHA.

Main Results:

• Oncogenic K-ras upregulates HDAC6 and c-myc expression.
• High HDAC6 levels correlate with activated K-ras mutations in colon cancer.
• K-ras-transformed cells exhibit resistance to SAHA-induced growth inhibition.
• K-ras inhibitors sensitize K-ras-mutated lung cancer cells to SAHA.
• Mutant K-ras induces HDAC6 expression via a MAP kinase-dependent pathway.

Conclusions:

• Oncogenic K-ras contributes significantly to SAHA resistance in solid tumors.
• Targeting K-ras in combination with SAHA may be a viable strategy to enhance therapeutic efficacy.
• This approach could improve patient selection and treatment outcomes for cancers with K-ras mutations.